KCM
XFOR icon

Kingdon Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Kingdon Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-933,332
Closed -$3.19M – 101
2025
Q3 		$3.19M Buy
933,332
+700,000
+300% +$1.81M 0.4% 68
2025
Q2 		$443K Sell
233,332
-1
-0% -$4 0.06% 66
2025
Q1 		$1.65M Buy
233,333
+68,766
+42% +$947K 0.18% 64
2024
Q4 		$3.62M Buy
164,567
+9,944
+6% +$159K 0.52% 59
2024
Q3 		$3.1M Buy
154,623
+500
+0.3% +$10.4K 0.34% 69
2024
Q2 		$2.68M Buy
154,123
+38,334
+33% +$1.25M 0.29% 72
2024
Q1 		$4.83M Hold
115,789
– – 0.53% 71
2023
Q4 		$2.91M Buy
115,789
+50,000
+76% +$1.22M 0.36% 66
2023
Q3 		$2.15M Hold
65,789
– – 0.25% 65
2023
Q2 		$3.83M Buy
+65,789
New +$3.38M 0.36% 67

Other funds holding XFOR

EAM
Empery Asset Management New York $86.5M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Kingdon Capital Management's XFOR Position: Q4 2025 in Review

Kingdon Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q4 2025, closing a stake of 933,332 shares — an estimated $3.19M sold.

Kingdon Capital Management first reported a position in XFOR in Q2 2023 and held it in 10 quarters. The position peaked at $4.83M in Q1 2024. 79 funds tracked by Wall St. Rank hold XFOR as of Q4 2025.

  • Kingdon Capital Management reported no remaining X4 Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Kingdon Capital Management sold 933,332 X4 Pharmaceuticals shares in Q4 2025, an estimated $3.19M.
  • Kingdon Capital Management first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 10 quarters.
  • Kingdon Capital Management's X4 Pharmaceuticals position peaked at $4.83M in Q1 2024.
  • 79 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2025.

Based on Kingdon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.